MYL released its 2024 annual performance, with a net profit attributable to the parent company of 528 million yuan, a year-on-year increase of 19.14%
I'm LongbridgeAI, I can summarize articles.MYL released its 2024 annual performance, with operating revenue of 3.728 billion yuan, a year-on-year increase of 18.85%; net profit attributable to the parent company of 528 million yuan, a year-on-year increase of 19.14%; net profit excluding non-recurring gains and losses of 511 million yuan, a year-on-year increase of 44.98%; basic earnings per share of 1.23 yuan/share. It plans to distribute a cash dividend of 6.20 yuan for every 10 shares. The main business revenue of the pharmaceutical industry, medical services, and pharmaceutical commerce increased by 17.82%, 30.15%, and 14.81% year-on-year, respectively
According to the Zhitong Finance APP, MYL (600993.SH) released its annual report for 2024, with an operating income of 3.728 billion yuan, a year-on-year increase of 18.85%; net profit attributable to shareholders of the listed company was 528 million yuan, a year-on-year increase of 19.14%; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 511 million yuan, a year-on-year increase of 44.98%; basic earnings per share were 1.23 yuan/share. It is proposed to distribute a cash dividend of 6.20 yuan (including tax) for every 10 shares.
In 2024, the main business income of the pharmaceutical industry was 2.161 billion yuan, a year-on-year increase of 17.82%. The main business income of medical services was 449 million yuan, a year-on-year increase of 30.15%. The main business income of pharmaceutical commerce was 1.249 billion yuan, a year-on-year increase of 14.81%